Clinical characteristics of type 2 diabetes in patients with mutations of HFE

Diabetes and Metabolism

Volumn 26, Issue 1, 2000, Pages 65-68

  Dubois Laforgue, D ^b   Caillat Zucman, S ^b   Boitard, C ^b   Timsit, J ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b NONE

Author keywords

Genetic hemochromatosis; HFE mutations; Insulin resistance; Iron metabolism; Obesity; Type 2 diabetes

Indexed keywords

ADULT; ARTICLE; DISEASE ASSOCIATION; FEMALE; GENE FREQUENCY; GENE MUTATION; HEMOCHROMATOSIS; HETEROZYGOSITY; HUMAN; INSULIN RESISTANCE; IRON METABOLISM; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY;

AMINO ACID SUBSTITUTION; ASPARTIC ACID; CYSTEINE; DIABETES MELLITUS, TYPE 2; FEMALE; FERRITINS; HETEROZYGOTE; HISTIDINE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HUMANS; INSULIN RESISTANCE; IRON; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MEMBRANE PROTEINS; MIDDLE AGED; POINT MUTATION; TRANSFERRIN; TYROSINE;

EID: 0034099430     PISSN: 03381684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Feder JN, Gnirke A, Thomas W, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet, 1996, 13, 399-408.
2. Tavill AS. Clinical implications of the hemochromatosis gene. N Engl J Med. 1999, 341, 755-757.
3. Yaouanq JM. Diabetes and haemochromatosis: current concepts, management and prevention. Diabetes Metab, 1995, 21, 319-329.
4. Niederau C, Berger M, Stremmel W, et al. Hyperinsulinemia in non-cirrhotic haemochromatosis: impaired hepatic degradation. Diabetologia, 1984, 26, 441-444.
5. Adams PC, Deugnier Y, Moirand R, Brissol P. The relationship between iron overload, clinical symptoms, and age in 410 patients with genetic hemochromatosis. Hepatology, 1997, 25, 162-166.
6. Beutler E. Genetic irony beyond haemochromatosis: clinical effects of HLA-H mutations. Lancet, 1997, 349, 296-297.
7. Nelson RL, Davis FG, Persky V, Becker E. Risk of neoplastic and other diseases among people with heterozygosity for hereditary hemochromatosis. Cancer, 1995, 76, 875-879.
8. Dubois-Laforgue D, Caillat-Zuckman S, Djilali-Saiah I, et al. Mutations in HFE, the hemochromatosis candidate gene, in patients with NIDDM. Diabetes Care, 1998, 21, 1371-1372.
9. Braun J, Donner H, Plock K, Rau H, Usadel KH, Badenhoop K. Hereditary haemochromatosis mutations (HFE) in patients with type II diabetes mellitus. Diabetologia, 1998, 41, 983-984.
10. Florkowski CM, George PM, Willis JA, et al. Hemochromatosis gene mutations Cys282Tyr and His63Asp are not increased in type 2 diabetic patients compared with the Canterbury (New Zealand) general population. Diabetes Res Clin pract, 1999, 43, 199-203.
11. Bulaj ZJ, Griffen LM, Jorde LB, Edwards CQ, Kushner JP. Clinical and biochemical abnormalities in people heterozygous for hemochromatosis. N Engl J Med, 1996, 335, 1799-1805.
12. Distante S, Berg JP, Lande K, Haug E, Bell H. High prevalence of the hemochromatosis-associated Cys282Tyr HFE gne mutation in a healthy Norwegian population in the city of Oslo, and phenotypic expression. Scand J Gastroenterol, 1999, 34, 529-534.
13. Burt MJ, George PM, Upton JD, et al. The significance of haemochromatosis gene mutations in the general population: implications for screening. Gut, 1998, 43, 830-836.
14. Aguilar Martinez P, Biron C. Masmejean C, Jeanjean P, Michel H, Schevd JF. Compound heterozygotes for hemochromatosis gne mutations: may they help to understand the pathophysiology of the disease? Blood Cell Mol Dis, 1997, 23, 269-276.
15. Tuomainen TP, Nyyssönen K, Salonen R, et al. Body iron stores are associated with serum insulin and blood glucose concentrations. Population study in 1013 eastern Finnish men. Diabetes Care, 1997, 20, 426-428.
16. Feder JN, Penny DM, Irrinke A, et al. The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding. Proc Natl Acad Sci, 1998, 95, 1472-1477.
17. Lebron JA, Bennett MJ, Vaughn DE, et al. Crystal structure of the hemochromatosis protein HFE and characterization of its interaction with transferrin receptor. Science, 1998, 93, 111-123.
18. Merkel PA, Simonson DC, Amiel SA, et al. Insulin resistance and hyperinsulinemia in patients with thalassemia major treated by hypertransfusion. N Engl J Med, 1988, 13, 809-814.
19. Moiran R, Mortaji AM, Loréal O, Paillard F, Brissot P, Deugnier Y. A new syndrome of liver iron overload with normal transferrin saturation. Lancet, 1997, 349, 95-98.
20. Fernandez-Real JM, Ricart-Engel W, Arroyo E, et al. Serum ferritin as a component of the insulin resistance syndrome. Diabetes Care, 1998, 21, 62-68.
21. Salonen JT, Tuomainen TP, Nyyssönen K, Lakka HM, Punnonen K. Relation between iron stores and non-insulin dependent diabetes in men: case-control study. BMJ, 1998, 317, 727.
22. Shafer AI, Cheron RG, Dluhy R, et al. Clinical consequence of acquired iron overload in adults. N Engl J Med, 1981, 304, 319-324.
23. Yki-Järvinen H. Pathogenesis of non-insulin-dependent diabetes mellitus. Lancet, 1994, 343, 91-95.
24. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care, 1997, 20, 1183-1197.